| Literature DB >> 32906736 |
Michele Antonelli1,2, Davide Donelli3,4, Grazia Barbieri5, Marco Valussi6, Valentina Maggini3, Fabio Firenzuoli3.
Abstract
The aim of this research work is to analyze the chemistry and diversity of forest VOCs (volatile organic compounds) and to outline their evidence-based effects on health. This research work was designed as a narrative overview of the scientific literature. Inhaling forest VOCs like limonene and pinene can result in useful antioxidant and anti-inflammatory effects on the airways, and the pharmacological activity of some terpenes absorbed through inhalation may be also beneficial to promote brain functions by decreasing mental fatigue, inducing relaxation, and improving cognitive performance and mood. The tree composition can markedly influence the concentration of specific VOCs in the forest air, which also exhibits cyclic diurnal variations. Moreover, beneficial psychological and physiological effects of visiting a forest cannot be solely attributed to VOC inhalation but are due to a global and integrated stimulation of the five senses, induced by all specific characteristics of the natural environment, with the visual component probably playing a fundamental role in the overall effect. Globally, these findings can have useful implications for individual wellbeing, public health, and landscape design. Further clinical and environmental studies are advised, since the majority of the existing evidence is derived from laboratory findings.Entities:
Keywords: biogenic volatile organic compounds; forest; limonene; phytoncides; pinene; preventive medicine; public health; review
Mesh:
Substances:
Year: 2020 PMID: 32906736 PMCID: PMC7559006 DOI: 10.3390/ijerph17186506
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Functions of constitutive and herbivore-induced forest Volatile Organic Compounds (VOCs).
| Constitutive Forest VOCs | Herbivore-Induced Plant Volatiles (HIPVs) |
|---|---|
| Reduction of abiotic stress. Isoprene and monoterpenes increase general thermal tolerance of photosynthesis, protect photosynthetic apparatus and its activity under high-temperature stress by stabilizing the thylakoid membranes and quenching Reactive Oxygen Species (ROS) | Reduction of abiotic stress. Isoprene and monoterpenes increase general thermal tolerance of photosynthesis, protect photosynthetic apparatus and its activity under high-temperature stress by stabilizing the thylakoid membranes and quenching Reactive Oxygen Species (ROS) |
| Defense against herbivores. Comprises toxic, repellent, anti-nutritive constitutive BVOCs (biogenic Volatile Organic Compounds) or HIPVs, as well as growth and reproductive reducers | Defense against herbivores, mainly indirectly but also directly. HIPVs and volatile compounds that attract, nourish, or otherwise favor another organism that reduces herbivore pressure |
| Inter-plant signaling. HIPVs, especially Green Leaf Volatiles (GLVs), and constitutive BVOCs can travel from a herbivore-damaged part to other plants (both conspecific and heterospecific), activating defense genes and priming a more vigorous response after an attack | Inter- and intra-plant signaling. HIPVs, especially GLVs, and constitutive BVOCs can travel from a herbivore-damaged part to an undamaged one, or to other plants (both conspecific and heterospecific), activating defense genes and priming a more vigorous response after an attack |
| Defense against microbial pathogens | Defense against microbial pathogens |
| Allelopathy. Inhibition of competing species’ seed germination and competition | |
| Attraction of pollinators and seed dispersers |
Figure 1BVOCs’ functions in relation to biotic and abiotic stresses. Adapted from Laothawornkitkul et al. (2009) [8].
Figure 2Main biosynthetic pathways for BVOCs. In green and yellow colors, the methylerythritol phosphate (MEP) and mevalonate (MVA) pathways to isoprenoids, respectively, in blue color, the lipoxygenase (LOX) pathway to GLVs, and in purple color, the shikimate pathway to aromatic compounds. Adapted from Maffei et al. (2011) [17].
Figure 3Atmospheric concentration of BVOCs under forest canopy [16,31,32,34,38,39,40,41,42,43,44]. Abbreviations: Tot. terpenes = total concentration of terpenes; LOX = products of the lipoxygenase (LOX) pathway.
Figure 4Atmospheric concentrations of seven monoterpenes under the canopy of a Scots pine forest [44].
Forest BVOCs and their chemical characteristics listed on the basis of the magnitude of emissions (in descending order).
| Molecule | Chemical Family | IUPAC | Formula | Structure | CAS number | Boiling Point (at 760 mmHg) | Molar Mass (g/mol) | I/C 1 | C/D 2 | E 3 | P 4 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Isoprene | Isoprenoids | 2-methylbuta-1,3-diene | C5H8 |
| 78-79-5 | 34.1 °C | 68.12 | C | D | **** | +++ |
| cis-3-Hexen-1-ol | GLVs | ( | C6H12O |
| 928-96-1 | 156.5 °C | 100.16 | I | D | *** | +++ |
| cis-3-Hexenal | GLVs | (Z)-hex-3-enal | C6H10O |
| 6789-80-6 | 126 °C | 98.14 | I | D | *** | +++ |
| cis-3-Hexenyl acetate | GLVs | [(Z)-hex-3-enyl] acetate | C8H14O2 |
| 3681-71-8 | 174.2 °C | 142.2 | I | D | *** | +++ |
| d-Limonene | Monoterpene hydrocarbons | (4R)-1-methyl-4-prop-1-en-2-ylcyclohexene | C10H16 |
| 65996-98-7 | 175.4 °C | 136.23 | C, I | D | *** | +/+++ |
| α-Pinene | Monoterpene hydrocarbons | 2,6,6-trimethylbicyclo[3.1.1]hept-2-ene | C10H16 |
| 67762-73-6 | 156 °C | 136.23 | C, I | D | *** | +/+++ |
| (E)-β-Ocimene | Monoterpene hydrocarbons | (3E)-3,7-dimethylocta-1,3,6-triene | C10H16 |
| 3779-61-1 | 175.2 °C | 136.23 | C, I | D | ** | +/++ |
| 1,8-Cineole | Monoterpenoid ethers | 1,3,3-trimethyl-2-oxabicyclo[2.2.2]octane | C10H18O |
| 470-82-6 | 176.4 °C | 154.25 | C, I | D | ** | |
| Camphor | Monoterpenoid ketones | 1,7,7-trimethylbicyclo[2.2.1]heptan-2-one | C10H16O |
| 76-22-2 | 205.7 °C | 152.23 | ** | |||
| Linalool | Monoterpenoid alcohol | 3,7-dimethylocta-1,6-dien-3-ol | C10H18O |
| 78-70-6 | 197.5 °C | 154.25 | C, L | D | ** | +/++ |
| p-Cymene | Aromatic monoterpene hydrocarbons | 1-methyl-4-propan-2-ylbenzene | C10H14 |
| 99-87-6 | 177 °C | 134.22 | C | D | ** | |
| Sabinene | Monoterpene hydrocarbons | 4-methylidene-1-propan-2-ylbicyclo[3.1.0]hexane | C10H16 |
| 3387-41-5 | 164 °C | 136.23 | C | D | ** | |
| β-Caryophyllene | Sesquiterpene hydrocarbons | (1R,4E,9S)-4,11,11-trimethyl-8-methylidenebicyclo[7.2.0]undec-4-ene | C15H24 |
| 87-44-5 | NA | 204.35 | C, I | D | ** | +/++ |
| β-Myrcene | Monoterpene hydrocarbons | 7-methyl-3-methylideneocta-1,6-diene | C10H16 |
| 123-35-3 | 167 °C | 136.23 | C | D | ** | |
| β-Pinene | Monoterpene hydrocarbons | 6,6-dimethyl-2-methylidenebicyclo[3.1.1]heptane | C10H16 |
| 127-91-3 | 166.0 °C | 136.234 | C, I | D | ** | |
| β 3-Carene | Monoterpene hydrocarbons | 3,7,7-trimethylbicyclo[4.1.0]hept-3-ene | C10H16 |
| 74806-04-5 | 171.4 °C | 136.234 | C | D | ** | |
| (E)-Linalool-oxide | Monoterpenoid oxide | 2-[(2S,5S)-5-ethenyl-5-methyloxolan-2-yl]propan-2-ol | C10H18O2 |
| 11063-78-8 | NA | 170.25 | C | D | * | |
| (Z)-Linalool-oxide | Monoterpenoid oxide | 2-(5-ethenyl-5-methyloxolan-2-yl)propan-2-ol | C10H18O2 |
| 14049-11-7 | 224.2 °C | 170.25 | C | D | * | |
| Borneol | Monoterpenoid alcohol | 1,7,7-trimethylbicyclo[2.2.1]heptan-2-ol | C10H18O |
| 464-45-9 | 212.0 °C | 154.25 | C | * | ||
| Bornyl acetate | Monoteropene-derived ester | (1,7,7-trimethyl-2-bicyclo[2.2.1]heptanyl) acetate | C12H20O2 |
| 20347-65-3 | 223.5 °C | 196.286 | C | * | ||
| Camphene | Monoterpene hydrocarbons | 2,2-dimethyl-3-methylidenebicyclo[2.2.1]heptane | C10H16 |
| 79-92-5 | 157.5 °C | 136.234 | C | D | * | |
| Terpinen-4-ol | Monoterpenoid alcohol | 4-methyl-1-propan-2-ylcyclohex-3-en-1-ol | C10H18O |
| 562-74-3 | 209.0 °C | 154.25 | C | * | ||
| α-Copaene | Sesquiterpene hydrocarbons | (1R)-1,3-dimethyl-8-propan-2-yltricyclo[4.4.0.02,7]dec-3-ene | C15H24 |
| 3856-25-5 | 248.5 °C | 204.35 | I | * | ||
| α-Humulene | Sesquiterpene hydrocarbons | (1E,4E,8E)-2,6,6,9-tetramethylcycloundeca-1,4,8-triene | C15H24 |
| 6753-98-6 | 166-168 °C | 204.35 | C | D | * | |
| α-Phellandrene | Monoterpene hydrocarbons | 2-methyl-5-propan-2-ylcyclohexa-1,3-diene | C10H16 |
| 99-83-2 | 171.5 °C | 136.234 | C | * | ||
| α-Terpinene | Monoterpene hydrocarbons | 1-methyl-4-propan-2-ylcyclohexa-1,3-diene | C10H16 |
| 99-86-5 | 174.1 °C | 136.234 | C | D | * | |
| α-Terpineol | Monoterpenoid alcohol | 2-(4-methylcyclohex-3-en-1-yl)propan-2-ol | C10H18O |
| 10482-56-1 | 217.5 °C | 154.249 | C | * | ||
| α-Terpinolene | Monoterpene hydrocarbons | 1-methyl-4-propan-2-ylidenecyclohexene | C10H16 |
| 1124-27-2 | 186.0 °C | 138.25 | C | D | * | |
| β-Phellandrene | Monoterpene hydrocarbons | 3-methylidene-6-propan-2-ylcyclohexene | C10H16 |
| 555-10-2 | 175 °C | 136.234 | C, I | * | +/+++ | |
| β-Terpinene | Monoterpene hydrocarbons | 1-methyl-4-propan-2-ylcyclohexa-1,4-diene | C10H16 |
| 99-85-4 | 183.0 °C | 136.234 | C, I | D | * | |
| (Z)-β-Ocimene | Monoterpene hydrocarbons | (3Z)-3,7-dimethylocta-1,3,6-triene | C10H16 |
| 13877-91-3 | 175.2 °C | 136.234 | C, I | D | +/++ | |
| Bergamotene | Sesquiterpene hydrocarbons | 6-methyl-2-methylidene-6-(4-methylpent-3-enyl)bicyclo[3.1.1]heptane | C15H24 |
| 7663-66-3 | NA | 208.38 | I | |||
| DMNT | Homoterpene hydrocarbons | 4,8-dimethylnona-1,3,7-triene | C11H18 |
| 19945-61-0 | 195.6 °C | 150.26 | I | +/++ | ||
| Longifolene | Sesquiterpene hydrocarbons | 3,3,7-trimethyl-8-methylidenetricyclo[5.4.0.02,9]undecane | C15H24 |
| 475-20-7 | 252.2 °C | 204.35 | C | D | ||
| Methyl jasmonate | Jasmonate ester | methyl 2-[(1R,2R)-3-oxo-2-[(Z)-pent-2-enyl]cyclopentyl]acetate | C13H20O3 |
| 39924-52-2 | 302.9 °C | 224.296 | I | |||
| Methyl salicylate | Benzoate ester | methyl 2-hydroxybenzoate | C8H8O3 |
| 119-36-8 | 222.0 °C | 152.147 | I | ++++ | ||
| TMTT | Homoterpene hydrocarbons |
(3 | C16H26 |
| 62235-06-7 | 293.2 °C | 218.38 | I | +/++ | ||
| α-Thujene | Monoterpene hydrocarbons | 2-methyl-5-propan-2-ylbicyclo[3.1.0]hex-2-en | C10H16 |
| 2867-05-2 | 152 °C | 136.23 | C | |||
| β-Farnesene | Sesquiterpene hydrocarbons | 7,11-dimethyl-3-methylidenedodeca-1,6,10-triene | C15H24 |
| 18794-84-8 | 279.6 °C | 204.35 | I | ++ |
1 I/C = Inducible/constitutive: forest VOC types. 2 C/D = Conifers/deciduous: tree types. 3 E = Emissions [: highly abundant emissions: ****; abundant emissions: ***; moderately abundant emissions: **; common emissions: *. 4 P = Persistence [: less than 10 min: +; 10–60 min: ++; 1 h–24 h: +++; more than 24 h: ++++.
Average content of D-limonene in some tree-derived essential oils [106].
| Plant Source | Botanical Family | Part of the Plant Used | Content (%) * |
|---|---|---|---|
| Burseraceae | Oleoresin | 28.0–45.0 | |
| Burseraceae | Oleoresin | 6.0–21.9 | |
| Burseraceae | Oleoresin | 58.6–63.3 | |
| Burseraceae | Oleoresin | 26.9–65.0 | |
| Lauraceae | Leaves | 13.9–22.5 | |
| Pinaceae | Leaves and branches | 28.5–54.7 | |
| Pinaceae | Leaves and branches | 29.6 | |
| Pinaceae | Leaves and branches | 6.1–37.1 | |
| Rutaceae | Fruit peel | 27.0–95.0 |
* Content (%) = the relative quantity, expressed as a range of percentages, of D-limonene included in tree-derived essential oils.
Summary of findings of clinical studies and preclinical experiments with animal models about anti-proliferative effects of D-limonene.
| Type | Doses | Results | Ref. |
|---|---|---|---|
| Animal model—mice | 25 mg orally | Limonene reduces mice stomach/lung tumors by 3% | [ |
| Animal model—rats | 7.5–10% diet | Breast cancer regression in 89% of animals | [ |
| Phase I—humans | 0.5–12 g/m2 | Partial response in breast cancer patients | [ |
| Phase II—humans | 8 g/m2 | No responses in patients with solid tumors | [ |
| Open-label—humans | 2 g/die | 22% reduction in cyclin D1 in early-stage breast cancer | [ |
Preclinical evidence of limonene biological activity.
| Functional Response | Model | Molecules/Mechanisms Involved in Targeted Pathways | Ref. |
|---|---|---|---|
|
| Murine raw 264.7 cell line | TNF-α, IL-1, IL-6 | [ |
| Human chondrocytes | NF-kB, NO, iNOS, p38, JNK | [ | |
| Human lens epithelial cells | ROS, CASP, MAPK, Bcl-2/Bax | [ | |
| Human neuroblastoma cells | LC3, clonogenic capacity | [ | |
| Fruit fly | NO | [ | |
| BALB/c mice | NO | [ | |
| BALB/c mice | Catalase, peroxidase | [ | |
| BALB/c mice | IL-5, IL-13, MCP-1, TGF-β | [ | |
| BALB/c mice | NF-kB, p38, JNK, ERK | [ | |
| Wistar rats | NF-kB, COX-2, iNOS | [ | |
| Swiss mice | IL-1β | [ | |
| Sprague–Dawley rats | COX2, ERK, iNOS, MMP-2, MMP-9, PGE, TGF-β | [ | |
| BALB/c mice | Apoptosis-related genes | [ | |
| Swiss mice | Oxidative stress | [ | |
|
| ICR mice | Elevated plus maze test | [ |
| Mice | Sleeping time | [ | |
| Swiss mice | MBT assay, anxiolytic effect | [ | |
| Rats | Locomotion, dopamine level | [ | |
| Rats | Immobility in forced swim test | [ | |
| CUMS mice | Body weight, sucrose preference, mobility | [ | |
| Elevated Plus Maze (EPM) test | [ | ||
|
| Swiss mice | Induced nociception | [ |
| ICR mice | Writhing test | [ | |
| Rats | Mechanical hyperalgesia | [ | |
| Swiss mice | Writhing test | [ | |
| Swiss mice | Mechanical hyperalgesia, IL-1β, TNF-α | [ |
Abbreviations: CASP, caspase; COX-2, cyclooxygenase-2; ERK, extracellular signal-regulated kinase; ICR, imprinted control region; IL, interleukin; iNOS, inducible NO synthase; JNK, c-jun N-terminal kinase; LC3, microtubule-associated protein light chain 3; MAPK, mitogen-activated protein kinase; MBT, marble burying test; MCP, monocyte chemoattractant protein; NF-kB, nuclear factor-B; NO, nitric oxide; p38, protein 38; PGE, prostaglandin E; ROS, reactive oxygen species; TGF, tumor growth factor; TNF, tumor necrosis factor.
Tree species whose total essential oil contains more than 20% of α-pinene [106].
| Plant Source | Botanical Family | Part of the Plant Used | Content (%) * |
|---|---|---|---|
| Burseraceae | Oleoresin | 41.7–80.0 | |
| Burseraceae | Oleoresin | 10.3–51.3 | |
| Cupressaceae | Leaves | 20.4–52.7 | |
| Cupressaceae | Fruit | 24.1–55.4 | |
| Cupressaceae | Leaves and branches | 41.8–53.5 | |
| Dipterocarpaceae | Wood | 54.3 | |
| Pinaceae | Cones | 18.0–31.7 | |
| Pinaceae | Leaves and branches | 38.5 | |
| Pinaceae | Leaves | 14.2–21.5 | |
| Pinaceae | Leaves and branches | 23.1–32.1 | |
| Pinaceae | Leaves | 4.1–31.5 | |
| Pinaceae | Leaves | 11.5–35.1 | |
| Pinaceae | Leaves and branches | 47.7–52.8 | |
| Pinaceae | Leaves | 30.8–36.8 | |
| Pinaceae | Leaves | 20.3–45.8 |
* Content (%) = the relative quantity, expressed as a range of percentages, of α-pinene included in tree-derived essential oils.
Tree species whose total essential oil contains more than 20% of β-pinene [106].
| Plant Source | Botanical Family | Part of the Plant Used | Content (%) * |
|---|---|---|---|
|
| Pinaceae | Cones | 3.0–22.5 |
| Pinaceae | Leaves and twigs | 28.1–56.1 | |
| Pinaceae | Leaves and twigs | 4.8–31.9 | |
| Pinaceae | Leaves and twigs | 23.0 | |
| Pinaceae | Leaves and twigs | 1.3–20.7 | |
| Pinaceae | Leaves and twigs | 28.9 | |
| Pinaceae | Leaves and twigs | 29.4–29.9 | |
| Pinaceae | Leaves and twigs | 31.1–33.3 | |
| Pinaceae | Leaves and twigs | 1.9–33.3 | |
| Pinaceae | Leaves and twigs | 20.8 | |
|
| Rutaceae | Fruit peel | 21.1 |
* Content (%) = the relative quantity, expressed as a range of percentages, of β-pinene included in tree-derived essential oils.
Preclinical evidence of α-pinene biological activity.
| Model | Target | Reference | |
|---|---|---|---|
|
| Murine macrophages | NF-kB, | [ |
| Human U373-MG cells | ROS, peroxidase | [ | |
| Human chondrocytes | NF-kB, | [ | |
| Human lymphocytes | Total antioxidant capacity | [ | |
| Mouse | Ig-E, IL-4 | [ | |
| Wistar rats | Superoxide dismutase, catalase, peroxidase, NO, IL-6 | [ | |
| C57BL/6 mice | CD4, CD8 and NK cells | [ | |
| Wistar rats | COX2 | [ | |
|
| Sprague–Dawley rats | Sleep rhythm | [ |
| Mice | BDNF, TH, EPM test | [ | |
| ICR and C57BL/6N mice | GABA BZD receptor, sleep behavior | [ | |
| Wistar–Kyoto mice | Forced swim test, oxidative phosphorylation expression | [ | |
| Wistar rats | Sensorimotor severity score | [ | |
| C57BL/6 mice | Schizophrenia-like behavior | [ | |
|
| BALB/c mice | Tail-flick test | [ |
| Mice | Neuropathic pain | [ | |
| Wistar rats | Nociception | [ |
Abbreviations: BDNF, brain-derived neurotrophic factor; BZD, benzodiazepine; EPM, elevated plus maze; ERK, extracellular signal-regulated kinase; GABA, γ-aminobutyric acid; Ig-E, immunoglobulin E; JNK, c-jun N-terminal kinase; MMP-1, metalloproteinase 1; MMP-13, metalloproteinase 13; NF-kB, nuclear factor-B; ROS, reactive oxygen species; TH, tyrosine hydroxylase.
Summary of preclinical evidence relative to biological activities of the five most common forest VOCs [3,30,34,35,36,37].
| Molecule | Effects | Mechanisms | References |
|---|---|---|---|
|
| Anti-inflammatory | It inhibits the synthesis or release of pro-inflammatory mediators (TNF-α, NO, IL-1β, IL-6, IL-5, IL-13, TGF-β), enzymes (5-LOX, COX-2, iNOS), transcription factors (NF-κB), and mitogen-activated protein (MAP) kinase family members (p38, JNK, ERK). | [ |
| Antioxidant | It inhibits caspase-3/caspase-9 activation, increases the activities of cell antioxidant enzymes (catalase, peroxidase) and the Bcl-2/Bax ratio. | [ | |
| Antiproliferative | It induces phase II carcinogen-metabolizing enzymes, inhibits prenyl-transferase activity, increases cell autophagy (via MAP1LC3B, mitochondrial death pathway, the PI3k/Akt pathway, and caspase-3 and -9 activity) and differentiation, reduces cyclin-D1 and increases TGF-β signaling, decreases tumor-induced immunosuppression, reduces circulating Vascular Endothelial Growth Factor (VEGF) and blocks the receptor VEGF-R1, increases DNA damage repair and PARP cleavage. It modulates the expression of the chemotactic protein MCP-1 and of the proteolytic enzymes MMP-2, MMP-9. | [ | |
| Antinociceptive | Bimodal activity: topically applied, it seems capable of eliciting pain, via interaction with TRPA1 ion channels, while in other modes of administration, it has shown antinociceptive effects in different experimental models. | [ | |
| Anxiolytic | It shows some degree of efficacy in mice and rat models. | [ | |
| Antidepressant | It shows some degree of efficacy in mice and rat models. | [ | |
|
| Anxiolytic, sedative | In several animal models, it enhances sleep by acting as a positive modulator for GABA-A-BZD receptors, prolonging GABAergic inhibitory signaling. | [ |
| Anti-inflammatory | It modulates NF-κB and IκBα, ERK, JNK, IL-1β, IL-6, iNOS (and NO secretions), MMP-1, MMP-13, COX-2. | [ | |
| Antioxidant | It reduces ROS production, caspase-3 activity, modulates superoxide dismutase, catalase, peroxidase activity, NO and IL-6 secretions. | [ | |
| Antiproliferative | It acts on efflux pumps responsible for multidrug-resistant tumors and on cell cycle arrest via the cyclin-B protein. | [ | |
| Analgesic | It shows some degree of efficacy in animal models. | [ | |
|
| Anxiolytic, | It binds to the GABA-A receptor, prolonging GABAergic inhibitory signaling. It showed efficacy in animal models. | [ |
| Anti-inflammatory | It modulates NF-κB and IκBα. | [ | |
| Antioxidant | It reduces ROS production, caspase-3 activity, MMP and NO activities. | [ | |
| Antiproliferative | It acts on efflux pumps responsible for multidrug-resistant tumors and on cell cycle arrest via the cyclin-B protein. | [ | |
|
| Anti-inflammatory | It modulates MAP kinases such as JNK, p38, and it inhibits the synthesis and release of PGE-2. | [ |
| Antiproliferative | It blocks hepatic carcinogenesis caused by aflatoxin. | [ | |
| Analgesic | It is analgesic in mice, and its action is blocked by naloxone, perhaps via the α-2 adrenoreceptor. | [ | |
| Sedative, myorelaxant | It is a muscle relaxant in mice, and it potentiates barbiturate sleep time at high doses. | [ | |
| Gastroprotective | It contributes to the integrity of the gastric mucosa, decreasing ulcerative lesions, attenuating lipid peroxidative damage, and preventing depletion of GSH, GR, and GPx. | [ | |
|
| Metabolism | As a food supplement, it reduces animal models’ body weight and increases adiponectin levels and receptor mRNA expression in the liver. | [ |
| Antiproliferative | It induces apoptosis in cancer cell lines (B16F10-Nex2 melanoma), chromatin condensation, cell shrinkage, apoptotic body formation, fragmentation of nucleus, and caspase-3 activation. | [ | |
| Antioxidant | It prevents AAPH-induced lipoperoxidation and inhibits the superoxide radical. | [ | |
| Antinociceptive | Weak effects on acetic acid-induced writhing in mice models. | [ | |
| Antihyperlipidemic | It reduces total and LDL-cholesterol and triglycerides in hyperlipidemic rats and in HepG2 cells, not by inhibiting HMG-CoA reductase but by increasing apolipoprotein AI expression, possibly via SREBP-1 upregulation and MTP inhibition. | [ |